Perbak Capital Boosts Stake in Bio-Rad Laboratories

Investment firm increases holdings in medical research company by over 170%

Mar. 14, 2026 at 9:06am

Got story updates? Submit your updates here. ›

Perbak Capital Partners LLP grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 171.7% in the third quarter, according to the company's recent 13F filing with the Securities and Exchange Commission. The firm now owns 8,582 shares of the medical research company's stock, worth approximately $2.4 million.

Why it matters

Bio-Rad Laboratories is a prominent player in the medical research industry, providing instruments, reagents and other products used in various scientific applications. Perbak Capital's significant increase in its stake suggests the investment firm sees strong potential in Bio-Rad's business and future prospects.

The details

Perbak Capital Partners acquired an additional 5,423 shares of Bio-Rad Laboratories during the third quarter, bringing its total holdings to 8,582 shares. This represents a 171.7% increase in the firm's position. Bio-Rad Laboratories accounts for approximately 0.4% of Perbak Capital's investment portfolio, making it the 24th largest holding.

  • Perbak Capital Partners increased its stake in Bio-Rad Laboratories during the third quarter of 2026.

The players

Perbak Capital Partners LLP

An investment management firm that has increased its holdings in Bio-Rad Laboratories, a prominent medical research company.

Bio-Rad Laboratories, Inc.

A global provider of life science research and clinical diagnostic products, operating in the Life Science and Clinical Diagnostics segments.

Got photos? Submit your photos here. ›

The takeaway

Perbak Capital's significant increase in its stake in Bio-Rad Laboratories suggests the investment firm sees strong potential in the medical research company's business and future prospects, underscoring the company's importance in the industry.